- Home
- INO vs TELA Comparison
INO vs TELA Comparison
Compare INO & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- TELA
- Stock Information
- Founded
- INO 1979
- TELA 2012
- Country
- INO United States
- TELA United States
- Employees
- INO N/A
- TELA N/A
- Industry
- INO Medical/Dental Instruments
- TELA Medical/Dental Instruments
- Sector
- INO Health Care
- TELA Health Care
- Exchange
- INO Nasdaq
- TELA Nasdaq
- Market Cap
- INO 69.3M
- TELA 70.1M
- IPO Year
- INO 1998
- TELA 2019
- Fundamental
- Price
- INO $2.38
- TELA $1.58
- Analyst Decision
- INO Buy
- TELA Buy
- Analyst Count
- INO 5
- TELA 3
- Target Price
- INO $8.80
- TELA $5.33
- AVG Volume (30 Days)
- INO 2.7M
- TELA 84.6K
- Earning Date
- INO 11-13-2025
- TELA 11-06-2025
- Dividend Yield
- INO N/A
- TELA N/A
- EPS Growth
- INO N/A
- TELA N/A
- EPS
- INO N/A
- TELA N/A
- Revenue
- INO $182,337.00
- TELA $75,323,000.00
- Revenue This Year
- INO N/A
- TELA $25.72
- Revenue Next Year
- INO $15,775.73
- TELA $22.03
- P/E Ratio
- INO N/A
- TELA N/A
- Revenue Growth
- INO N/A
- TELA 16.34
- 52 Week Low
- INO $1.30
- TELA $0.86
- 52 Week High
- INO $7.00
- TELA $3.26
- Technical
- Relative Strength Index (RSI)
- INO 55.04
- TELA 41.78
- Support Level
- INO $2.33
- TELA $1.51
- Resistance Level
- INO $2.98
- TELA $1.73
- Average True Range (ATR)
- INO 0.22
- TELA 0.15
- MACD
- INO -0.01
- TELA -0.01
- Stochastic Oscillator
- INO 43.93
- TELA 13.58
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.